STOCK TITAN

CapsoVision (CV) director receives 4,045 RSU equity award

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Tsai Chen Lung reported acquisition or exercise transactions in this Form 4 filing.

CapsoVision, Inc. director Tsai Chen Lung reported receiving a grant of 4,045 Restricted Stock Units on March 19, 2026. Each RSU represents a contingent right to receive one share of CapsoVision common stock, giving him rights to 4,045 underlying shares after this award.

The RSUs vest in two equal installments, with 50% scheduled to vest on June 30, 2026 and the remaining 50% on December 31, 2026, subject to his continued service on the board through each vesting date. Following this grant, he holds 4,045 RSUs directly.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Tsai Chen Lung

(Last)(First)(Middle)
C/O CAPSOVISION, INC.
18805 COX AVENUE, SUITE 250

(Street)
SARATOGA CALIFORNIA 95070

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CapsoVision, Inc [ CV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/19/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Unit (RSU)(1)03/19/2026A4,045 (2) (2)Common Stock4,045$04,045D
Explanation of Responses:
1. Each Restricted Stock Unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock.
2. These RSUs are scheduled to vest as to 50% of the RSUs on June 30, 2026 and as to 50% of the RSUs on December 31, 2026 subject to the Non-Employee Director's continued service on the Board through such vesting date.
Remarks:
/s/ Kang-Huai (Johnny) Wang, Attorney-in-Fact for Tsai Chen Lung03/23/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did CapsoVision (CV) report for Tsai Chen Lung?

CapsoVision director Tsai Chen Lung received 4,045 Restricted Stock Units (RSUs). The grant occurred on March 19, 2026 and represents compensation in equity form, with each RSU tied to one share of CapsoVision common stock upon vesting.

How many CapsoVision (CV) shares are linked to the new RSU grant?

The grant covers rights to 4,045 underlying CapsoVision common shares. Each RSU converts into one share of common stock upon vesting, so the award provides contingent rights equivalent to 4,045 shares, assuming all vesting conditions are satisfied.

When do Tsai Chen Lung’s CapsoVision (CV) RSUs vest?

The RSUs vest in two equal installments during 2026. Half of the 4,045 RSUs are scheduled to vest on June 30, 2026, and the remaining half on December 31, 2026, contingent on continued board service through each vesting date.

What conditions apply to the CapsoVision (CV) RSU award for Tsai Chen Lung?

Vesting is conditioned on continued board service. The RSUs are scheduled to vest 50% on June 30, 2026 and 50% on December 31, 2026, only if Tsai Chen Lung continues serving as a non-employee director through those respective dates.

Is the CapsoVision (CV) Form 4 transaction a market purchase or sale?

The transaction is a grant of RSUs, not a market trade. It is reported with code “A”, meaning a grant or award acquisition, so there was no open-market buying or selling of CapsoVision shares associated with this filing.

How many CapsoVision (CV) RSUs does Tsai Chen Lung hold after this filing?

After the grant, he holds 4,045 RSUs directly. The Form 4 shows total derivative holdings following the transaction equal to 4,045 Restricted Stock Units, all tied to CapsoVision common stock and subject to the stated vesting schedule.
CapsoVision, Inc.

NASDAQ:CV

View CV Stock Overview

CV Rankings

CV Latest News

CV Latest SEC Filings

CV Stock Data

431.98M
27.71M
Medical Devices
Electromedical & Electrotherapeutic Apparatus
Link
United States
SARATOGA